These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22414856)

  • 1. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling.
    Liu Y; Webb HK; Fukushima H; Micheli J; Markova S; Olson JL; Kroetz DL
    J Pharmacol Exp Ther; 2012 Jun; 341(3):725-34. PubMed ID: 22414856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway.
    Liu Y; Lu X; Nguyen S; Olson JL; Webb HK; Kroetz DL
    Mol Pharmacol; 2013 Dec; 84(6):925-34. PubMed ID: 24092818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.
    Fife KL; Liu Y; Schmelzer KR; Tsai HJ; Kim IH; Morisseau C; Hammock BD; Kroetz DL
    J Pharmacol Exp Ther; 2008 Dec; 327(3):707-15. PubMed ID: 18815352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in soluble epoxide hydrolase (sEH) during cisplatin-induced acute renal failure in mice.
    Hashimoto T; Fang YI; Ohata H; Honda K
    J Toxicol Sci; 2015 Aug; 40(4):451-7. PubMed ID: 26165641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.
    Chen G; Xu R; Wang Y; Wang P; Zhao G; Xu X; Gruzdev A; Zeldin DC; Wang DW
    Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E563-75. PubMed ID: 22739108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
    Motoki A; Merkel MJ; Packwood WH; Cao Z; Liu L; Iliff J; Alkayed NJ; Van Winkle DM
    Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2128-34. PubMed ID: 18835921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase.
    Parrish AR; Chen G; Burghardt RC; Watanabe T; Morisseau C; Hammock BD
    Cell Biol Toxicol; 2009 Jun; 25(3):217-25. PubMed ID: 18386137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice.
    Zhu Y; Blum M; Hoff U; Wesser T; Fechner M; Westphal C; Gürgen D; Catar RA; Philippe A; Wu K; Bubalo G; Rothe M; Weldon SM; Dragun D; Schunck WH
    PLoS One; 2016; 11(1):e0145645. PubMed ID: 26727266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
    Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
    Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-ribose ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice.
    Ueki M; Ueno M; Morishita J; Maekawa N
    Tohoku J Exp Med; 2013 Mar; 229(3):195-201. PubMed ID: 23438786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling.
    Merkel MJ; Liu L; Cao Z; Packwood W; Young J; Alkayed NJ; Van Winkle DM
    Am J Physiol Heart Circ Physiol; 2010 Feb; 298(2):H679-87. PubMed ID: 20008276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury.
    Bettaieb A; Koike S; Chahed S; Zhao Y; Bachaalany S; Hashoush N; Graham J; Fatima H; Havel PJ; Gruzdev A; Zeldin DC; Hammock BD; Haj FG
    FEBS J; 2017 Jul; 284(13):1970-1986. PubMed ID: 28485854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Epoxide Hydrolase Inhibitor Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Improves Survival in Mice.
    Zhou Y; Liu T; Duan JX; Li P; Sun GY; Liu YP; Zhang J; Dong L; Lee KSS; Hammock BD; Jiang JX; Guan CX
    Shock; 2017 May; 47(5):638-645. PubMed ID: 27753791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Epoxide Hydrolase Inhibition Attenuates Excitotoxicity Involving 14,15-Epoxyeicosatrienoic Acid-Mediated Astrocytic Survival and Plasticity to Preserve Glutamate Homeostasis.
    Kuo YM; Hsu PC; Hung CC; Hu YY; Huang YJ; Gan YL; Lin CH; Shie FS; Chang WK; Kao LS; Tsou MY; Lee YH
    Mol Neurobiol; 2019 Dec; 56(12):8451-8474. PubMed ID: 31257558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increases in levels of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EETs and DHETs) in liver and heart in vivo by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in hepatic EET:DHET ratios by cotreatment with TCDD and the soluble epoxide hydrolase inhibitor AUDA.
    Diani-Moore S; Ma Y; Gross SS; Rifkind AB
    Drug Metab Dispos; 2014 Feb; 42(2):294-300. PubMed ID: 24311719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.
    Revermann M; Schloss M; Barbosa-Sicard E; Mieth A; Liebner S; Morisseau C; Geisslinger G; Schermuly RT; Fleming I; Hammock BD; Brandes RP
    Arterioscler Thromb Vasc Biol; 2010 May; 30(5):909-14. PubMed ID: 20224052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.
    Yu Z; Xu F; Huse LM; Morisseau C; Draper AJ; Newman JW; Parker C; Graham L; Engler MM; Hammock BD; Zeldin DC; Kroetz DL
    Circ Res; 2000 Nov; 87(11):992-8. PubMed ID: 11090543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.
    Elmarakby AA; Faulkner J; Pye C; Rouch K; Alhashim A; Maddipati KR; Baban B
    Clin Sci (Lond); 2013 Oct; 125(7):349-59. PubMed ID: 23611540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.
    Kim J; Yoon SP; Toews ML; Imig JD; Hwang SH; Hammock BD; Padanilam BJ
    Am J Physiol Renal Physiol; 2015 Jan; 308(2):F131-9. PubMed ID: 25377915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble epoxide hydrolase: a novel therapeutic target in stroke.
    Zhang W; Koerner IP; Noppens R; Grafe M; Tsai HJ; Morisseau C; Luria A; Hammock BD; Falck JR; Alkayed NJ
    J Cereb Blood Flow Metab; 2007 Dec; 27(12):1931-40. PubMed ID: 17440491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.